Concepedia

Elizabeth A. Harrington

EA

Statistics

Publications

54

Citations

6.9K

H-Index

32

Active since

1972

Affiliations

AstraZeneca (United Kingdom)(Current)

AstraZeneca (United States)

AstraZeneca (Singapore)

The Christie NHS Foundation Trust

Merck & Co., Inc., Rahway, NJ, USA (United States)

Elizabeth A. Harrington is an author at AstraZeneca (United Kingdom) specializing in medicine, oncology, and molecular oncology.

Publications per year

1972–2025

54

Publications

54

VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo

Elizabeth A. Harrington, David Bebbington, Jeffrey R. Moore et al. · Nature Medicine · 2004 · 954 citations · Full text

Medicine, Oncology, Pharmacology +13

Cooperative interaction between c-myc and bcl-2 proto-oncogenes

Abdallah Fanidi, Elizabeth A. Harrington, Gérard I. Evan · Nature · 1992 · 767 citations

Medicine, Cell Biology, Molecular Biology +14

c‐Myc‐induced apoptosis in fibroblasts is inhibited by specific cytokines.

Elizabeth A. Harrington, Martin R. Bennett, Abdallah Fanidi et al. · The EMBO Journal · 1994 · 747 citations · Full text

Life Sciences, Cell Biology, Molecular Genetics +14

Induction of apoptosis by the Bcl-2 homologue Bak

Thomas W. Chittenden, Elizabeth A. Harrington, Rosemary O’Connor et al. · Nature · 1995 · 734 citations

Life Sciences, Cell Biology, Molecular Biology +11

Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer

Noel W. Clarke, Andrew J. Armstrong, Antoine Thiery-Vuillemin et al. · NEJM Evidence · 2022 · 394 citations

Medicine, Oncology, Pharmacology +17

1–5 of 54